advertisement
Abstract #26548 Published in IGR 12-3
Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol
Garca-Feijo J; Senz-Frances F; Martnez-De-La-Casa JM; Mendez-Hernndez C; Fernndez-Vidal A; Calvo-Gonzlez C; Garca-Snchez JCurrent Medical Research and Opinion 2010; 26: 1599-1606
Objective: To compare brimonidine/timolol fixed combination (BrTFC; Combigan*) with dorzolamide/timolol fixed combination (DTFC; Cosopt(dagger)) in terms of ability to lower intraocular pressure (IOP) in primary open-angle glaucoma (POAG). Methods: This was a prospective, randomized, double-masked, crossover study. After 6 weeks of therapy with timolol maleate 0.5 twice daily, patients were randomized to BrTFC twice daily or DTFC twice daily for 6 weeks, before being crossed over to the other treatment arm for a further 6 weeks. At all follow-up visits, IOP was measured at 09.00 (pre-instillation) 12.00 and 16.00. The primary outcome measure was change in mean diurnal IOP from baseline at 6 weeks. The secondary outcome was percentage of patients with IOP <18mmHg at 6 weeks. Data were analyzed from all patients who completed the study. Results: Twenty-five patients were randomized and 20 completed the study. Mean diurnal IOP (meanstandard deviation [SD]) was 20.282.03mmHg at timolol-treated baseline. After 6 weeks, mean diurnal IOP was 16.282.07mmHg following BrTFC and 17.232.29mmHg following DTFC (difference: 0.95mmHg, 95 CI 0.101.80, p0.03). Mean IOP at 09.00 was 20.952.31mmHg at baseline. This was reduced to 15.852.56mmHg following BrTFC and 17.552.67mmHg following DTFC (difference: 1.70, 95 CI 0.802.60, p0.001). For the 12.00 and 16.00 timepoints, the mean changes from baseline in the two arms were comparable. Percentages of patients achieving a target IOP of <18mmHg were 85 following BrTFC and 60 following DTFC (pNS [not significant]). No treatment-related adverse events were reported with either therapy. Key limitations include the small size of the study population and the 6-week duration of treatment periods, which prevents drawing conclusions regarding long-term therapy. Conclusion: Reductions from baseline in mean diurnal IOP and morning IOP were greater with BrTFC than with DTFC.
F. Senz-Frances. Hospital Clnico Universitario San Carlos, Universidad Complutense, Madrid, Spain. federicosaenzfrancessb@gmail.com
Classification:
11.13.3 Betablocker and brimonidine (Part of: 11 Medical treatment > 11.13 Combination therapy)
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)
